Albemarle clear analyst consensus picture, shares trade in volatile lithium sector

Albemarle opens the week on the NYSE with a clear analyst consensus and heightened attention on lithium prices, as investors weigh valuation, earnings outlook and sector volatility against peers such as SQM and Livent.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 09:03.

Albemarle (US0126531013) starts the week on the New York Stock Exchange with analysts broadly constructive on the lithium producer despite a volatile price environment for battery metals. Consensus data compiled by MarketScreener on 2026-06-21 show a majority of analysts rating the shares Buy or Outperform with an average 12-month price target clearly above the current market price.MarketScreener consensus overview for Albemarle

What recent analyst data show

According to the MarketScreener consensus as of 2026-06-21, 19 out of 32 analysts covering Albemarle recommend Buy or Outperform, 10 are Neutral and 3 rate the stock Sell, with an average target price around 214 US dollars per share compared with a recent quote near 157 US dollars.MarketScreener consensus data This implies a consensus upside potential in the mid-30-percent range versus the latest trading price, underlining that research houses still see value in the lithium specialist despite the sharp correction from the 2022 peak levels.

In a sector note dated 2026-06-18, UBS reaffirmed its positive stance on lithium producers, highlighting Albemarle’s scale, integrated resource base in Chile and Australia and its long-term contracts with major electric-vehicle manufacturers as key supports for medium-term earnings visibility, even as spot lithium prices remain well below the 2021-2022 highs.UBS sector research on lithium producers

Consensus earnings outlook and valuation

On the earnings side, analysts on average expect Albemarle to generate 2026 earnings per share clearly below the exceptional profit levels achieved during the lithium price spike of 2022 but still robust on an historical basis, with MarketScreener data indicating a normalized earnings profile supported by long-term supply contracts and gradual capacity expansions in key assets.MarketScreener financial estimates for Albemarle Based on these consensus projections, the stock trades on a forward price-earnings multiple in the low-to-mid teens, which several analysts describe as undemanding given Albemarle’s position as one of the largest global lithium suppliers.

Bloomberg data place Albemarle’s market capitalization in the mid-18-billion-US-dollar range as of the latest close, putting it ahead of several pure-play peers but still well below diversified mining giants exposed to battery metals, which shapes the way large funds use the stock within broader clean-energy and energy-transition portfolios.Bloomberg profile for Albemarle

The product behind the stock

Albemarle generates the bulk of its revenue from specialty chemicals, with lithium products for rechargeable batteries at the core of its current growth story. The company supplies lithium compounds such as lithium hydroxide and lithium carbonate to major electric-vehicle and battery manufacturers, complemented by bromine and catalysts businesses that provide additional cash flow diversification alongside the high-profile battery materials segment.

Where the stock trades today

The Albemarle shares (US0126531013) most recently traded on the NYSE at 156.69 US dollars as of 2026-06-22, 22:00 New York time, according to closing data compiled by PandaForecast based on exchange prices.PandaForecast quote summary for Albemarle

Albemarle at a glance

• Company: Albemarle Corp.
• ISIN: US0126531013
• WKN: 890167
• Ticker: ALB
• Trading venue: NYSE
• Price (as of 2026-06-22, 22:00): 156.69 USD
• Market cap: approximately 18.0 billion USD (as of 2026-06-22)
• Sector / industry: Materials - Specialty Chemicals / Battery Materials
• Index membership: S&P 500
• Next earnings date: not officially scheduled

Disclaimer: This article is for informational purposes only and does not constitute investment advice, an offer or a recommendation to buy or sell securities. All data are based on sources deemed reliable but cannot be guaranteed. Investors should conduct their own research and, where appropriate, consult a qualified financial adviser.